<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997477</url>
  </required_header>
  <id_info>
    <org_study_id>CFOR258FTR03</org_study_id>
    <nct_id>NCT00997477</nct_id>
  </id_info>
  <brief_title>Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics</brief_title>
  <official_title>A Single Arm, 12 Week, Multicentre, Open Label, Phase IV Study to Evaluate Correct Use of and Patient Satisfaction From Sequential Use of Formoterol and Budesonide Inhaler Capsules Via Aerolizer™ Device in Patients With Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the correct use of sequential formoterol and budesonide inhaler
      capsule treatment via Aerolizer and patient satisfaction in adult asthmatics.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proper use of Foradil Combi</measure>
    <time_frame>Day 0, Day 30, Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma control test</measure>
    <time_frame>Day 0, Day 30, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of use: FSI-10 Questionnaire</measure>
    <time_frame>Day 30, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction: PSAM and FSI-10</measure>
    <time_frame>Evaluations will be made at visit 2 (Day 30± 1) and 3 (Day 90± 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events and severe adverse events</measure>
    <time_frame>3 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol and Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foradil Combi (Formoterol-budesonide)</intervention_name>
    <arm_group_label>Formoterol and Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate persistent asthmatic patients.

          -  No previous Aerolizer experience.

        Exclusion Criteria:

          -  Life-threatening asthma: A subject must not have life-threatening asthma as a history
             of significant asthma episode(s)requiring intubation associated with hypercapnia,
             respiratory arrest or hypoxic seizures, or asthma-related syncopal episode(s).

          -  Worsening of asthma: A subject must not have experienced a worsening of asthma which
             involved a hospitalization within 6 months of screening, or an emergency room visit
             three or more times in the past 6 months, or use of oral corticosteroids for worsening
             asthma within 3 months of screening.

          -  Unstable asthma: During screening period, a patient requires the use of &gt;8 puffs/day
             of salbutamol 100 mcg per actuation pMDI on two consecutive days.

          -  A subject must not have had an upper respiratory tract infection within 4 weeks of
             screening.

          -  FEV1&lt; 60% at screening.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novarits Investigator Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <name_title>Medical Department</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>aerolizer</keyword>
  <keyword>formoterol</keyword>
  <keyword>budesonide</keyword>
  <keyword>asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

